IV NAD+ drips are now sold in wellness clinics as a shortcut to energy, focus and slower aging. A new systematic review in Ageing Research Reviews asked what the published evidence supports. The answer for infusions is blunt: the authors found no eligible outcome trials of intravenous or intramuscular NAD+ for anti-aging or wellness. For oral NMN and NR, the evidence is better but still falls short of the marketing.
What NAD+ Is and Why It Declines
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme found in every cell. It takes part in energy metabolism and in the activity of enzymes involved in DNA repair and stress responses. Levels appear to fall with age, and that observation drives the whole "NAD+-boosting" market.
The strategies fall into three groups:
- Lifestyle approaches, such as exercise and diet.
- Oral precursors, mainly nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), which the body converts into NAD+.
- Parenteral NAD+, given by IV or intramuscular injection in some wellness settings.
The review (Gallagher and Emmanuel, 2026) is a PRISMA-guided systematic review, so it used a structured, predefined method to find and screen studies. It does not simply collect favorable papers.
What the Review Included
The authors searched peer-reviewed human and rodent intervention studies published from January 2010 to October 2025. They found 113 eligible studies:
- 33 human studies, of which 28 were randomized and 5 were nonrandomized
- 80 rodent studies
So the rodent literature is more than twice the size of the human literature. Most of the excitement around NAD+ comes from animal work.
Rodent Findings vs. Human Findings
In rodents: frequent benefits
In rodent models, raising NAD+ was often linked with improvements in metabolic, mitochondrial, inflammatory and functional outcomes. The authors add that effects varied across models and endpoints, so even the animal data are not uniformly positive.
In humans: the biomarkers move, the outcomes often don't
In people, the review reached two conclusions.
1. Oral NR and NMN reliably do something biochemically. Across trials, they consistently showed "target engagement." Circulating NAD-related metabolites (in plasma or whole blood) or cellular levels (for example in PBMCs, a type of white blood cell) rose. They were also generally well tolerated over weeks to months.
2. The downstream results are inconsistent. Effects on functional, metabolic, vascular and other healthspan-relevant outcomes were described as "heterogeneous and often null or endpoint-specific." In plain terms, a supplement can raise a blood marker without improving how you feel, perform or age. Some trials may show a benefit on one measure while others find nothing.
This gap between biomarker and benefit is the central point for buyers. A higher NAD-metabolite reading shows the molecule is absorbed and processed. It does not show you will gain strength, glucose control, vascular health or longevity.
IV and IM NAD+: A Large Evidence Gap
The review found no eligible outcome trials testing intravenous or intramuscular NAD+ itself for anti-aging or wellness purposes. Only two items touched on the parenteral route:
- One nonrandomized intravenous NMN study met inclusion criteria. It mainly offered short-term safety and biomarker information.
- An IV NAD+ pharmacokinetic pilot was noted as contextual evidence only, because it lacked eligible clinical outcomes.
This does not prove drips don't work. It means nobody has shown, in a controlled trial with meaningful endpoints, that they do. Short-term safety and pharmacokinetic data tell us what happens to the molecule in the body. They do not tell us whether a patient will be healthier or feel better afterward. Any improvement a client notices after a session could reflect expectation, the rest and hydration of sitting for an hour, or something else entirely, and without trials these can't be separated.
The authors say larger, well-designed randomized trials with longer follow-up and prespecified, clinically meaningful endpoints are needed, "particularly for parenteral approaches."
Practical Takeaways for Buyers
Typical oral doses in trials
For general context, human trials of oral precursors have mostly used the following ranges. These are not recommendations:
- NR: roughly 300 to 1,000 mg per day
- NMN: roughly 250 to 1,000 mg per day
These figures show what has been studied, not what is optimal. The review does not identify a dose that reliably produces functional benefits.
What to realistically expect
- Likely: higher blood or cellular NAD-related metabolites, and good short-term tolerability in studied populations.
- Uncertain: improvements in strength, metabolic markers, vascular function or biological aging. Results so far are mixed and often null.
- Unproven: any outcome benefit from IV or IM NAD+.
Treat any product claiming dramatic rejuvenation with skepticism. Oral trials ran weeks to months, so long-term safety and benefit are still open questions.
The cost question
Prices vary widely by clinic and dose. IV NAD+ sessions are commonly advertised at hundreds of dollars each, and protocols often involve multiple sessions. Oral NR or NMN typically costs far less per month. Given that neither route has strong outcome data, paying for the more expensive and less-studied route carries a clear opportunity cost. If you try a precursor, a modest oral trial with a clear personal goal (such as a lab marker or a specific performance measure) is easier to evaluate than a prepaid drip package.
Talk to a clinician first
People with cancer histories, those on medications, and anyone pregnant or nursing should seek medical advice before using NAD-boosting products. The review's tolerability findings apply to the trial populations studied.
Limitations Worth Noting
The review covers studies through October 2025, and the human literature is small and varied in doses, durations, populations and endpoints, which limits direct comparison. The lead author discloses ownership of a management company serving an aesthetics clinic that does not offer NAD+ infusions or supplements, and the authors report no other competing interests.
Bottom Line
NAD+ augmentation shows clear biological activity, but the review concludes that clinical effectiveness for anti-aging or wellness remains inconclusive. Oral NR and NMN have real biochemical effects and reasonable short-term tolerability. IV NAD+ has no outcome trials to support it. Until those trials exist, the drip is a bet on biology and not an evidence-backed intervention.